Brought to you by 
Oncoethix gets rights to Mitsubishi Tanabe's bromodomain inhibitor for cancer
28 Jun 2012
Executive Summary
Mitsubishi Tanabe Pharma Corp. has granted Oncoethix SA (oncology) exclusive worldwide rights, excluding certain Asian territories, to its Phase I small-molecule bromodomain inhibitor indicated for hematological malignancies. Oncoethix has coded the compound OTX015.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Oncoethix gets rights to Mitsubishi Tanabe's bromodomain inhibitor for cancer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice